[HTML][HTML] Pathogenesis of human cytomegalovirus in the immunocompromised host
P Griffiths, M Reeves - Nature Reviews Microbiology, 2021 - nature.com
Human cytomegalovirus (HCMV) is a herpesvirus that infects~ 60% of adults in developed
countries and more than 90% in developing countries. Usually, it is controlled by a vigorous …
countries and more than 90% in developing countries. Usually, it is controlled by a vigorous …
The middle east respiratory syndrome (MERS)
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a new zoonotic human
viral pathogen endemic to the Middle East. 1–3 It was identified in 2012 in a lung sample of …
viral pathogen endemic to the Middle East. 1–3 It was identified in 2012 in a lung sample of …
Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial
Importance Valganciclovir for 200 days is standard care for cytomegalovirus (CMV)
prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an …
prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an …
Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
RR Razonable, A Humar - Clinical transplantation, 2019 - Wiley Online Library
Cytomegalovirus (CMV) is one of the most common opportunistic infections that affect the
outcome of solid organ transplantation. This updated guideline from the American Society of …
outcome of solid organ transplantation. This updated guideline from the American Society of …
The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation
Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common
complications affecting solid organ transplant recipients, conveying higher risks of …
complications affecting solid organ transplant recipients, conveying higher risks of …
Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation
FM Marty, P Ljungman, RF Chemaly… - … England Journal of …, 2017 - Mass Medical Soc
Background Cytomegalovirus (CMV) infection remains a common complication after
allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the …
allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the …
Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials
P Ljungman, M Boeckh, HH Hirsch… - Clinical Infectious …, 2016 - academic.oup.com
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and
mortality in transplant recipients. For the purpose of developing consistent reporting of CMV …
mortality in transplant recipients. For the purpose of developing consistent reporting of CMV …
[HTML][HTML] Infection in organ transplantation
JA Fishman - American Journal of Transplantation, 2017 - Elsevier
The prevention, diagnosis, and management of infectious disease in transplantation are
major contributors to improved outcomes in organ transplantation. The risk of serious …
major contributors to improved outcomes in organ transplantation. The risk of serious …
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation
Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ
transplantation, resulting in significant morbidity, graft loss, and adverse outcomes …
transplantation, resulting in significant morbidity, graft loss, and adverse outcomes …
[HTML][HTML] Cytomegalovirus in solid organ transplantation
RR Razonable, A Humar - American journal of transplantation, 2013 - amjtransplant.org
Cytomegalovirus (CMV) is a ubiquitousherpes virus that infects the majority of humans (1).
The seroprevalence rates of CMV ranges from 30–97%(2, 3). Primary infection manifests as …
The seroprevalence rates of CMV ranges from 30–97%(2, 3). Primary infection manifests as …